Ipsen Past Earnings Performance

Past criteria checks 3/6

Ipsen has been growing earnings at an average annual rate of 22%, while the Pharmaceuticals industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 6.1% per year. Ipsen's return on equity is 16.2%, and it has net margins of 18.7%.

Key information

22.0%

Earnings growth rate

22.2%

EPS growth rate

Pharmaceuticals Industry Growth16.3%
Revenue growth rate6.1%
Return on equity16.2%
Net Margin18.7%
Next Earnings Update24 Jul 2024

Recent past performance updates

Recent updates

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Mar 26
Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

Dec 30
Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Dec 11
These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

Sep 28
Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Sep 07
These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Jun 21
Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Jun 02
Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Ipsen's (EPA:IPN) Dividend Will Be €1.20

May 12
Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Mar 19
Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Mar 01
Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Jan 19
Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Dec 08
Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Nov 02
We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Oct 14
Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

Aug 01
Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Jul 10
Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

May 26
Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

May 04
Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

Apr 19
Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

Is Ipsen (EPA:IPN) A Risky Investment?

Apr 18
Is Ipsen (EPA:IPN) A Risky Investment?

Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Mar 18
Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 50% Undervaluation?

Feb 14
Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 50% Undervaluation?

Ipsen (EPA:IPN) Has A Rock Solid Balance Sheet

Nov 04
Ipsen (EPA:IPN) Has A Rock Solid Balance Sheet

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Aug 05
We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Ipsen S.A. (EPA:IPN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Jul 15
Ipsen S.A. (EPA:IPN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Revenue & Expenses Breakdown
Beta

How Ipsen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTPA:IPN Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 233,3066171,135619
30 Jun 233,2824061,105528
31 Mar 233,2195001,072487
31 Dec 223,1565931,039445
30 Sep 223,0536561,007436
30 Jun 222,950719975427
31 Mar 222,849675946425
31 Dec 212,749631916424
30 Sep 212,712626923422
30 Jun 212,676622931420
31 Mar 212,681585951413
31 Dec 202,686548972406
30 Sep 202,697249986404
30 Jun 202,707-501,000403
31 Mar 202,700-531,010396
31 Dec 192,693-551,021389
30 Sep 192,6051761,003363
30 Jun 192,516406986337
31 Mar 192,432397970319
31 Dec 182,348388954302
30 Sep 182,258365931292
30 Jun 182,167343909281
31 Mar 182,090307883274
31 Dec 172,012270858266
30 Sep 171,923243821264
30 Jun 171,834217785262
31 Mar 171,753221752247
31 Dec 161,671226719231
30 Sep 161,623229703214
30 Jun 161,575233687196
31 Mar 161,548211676194
31 Dec 151,520189666193
30 Sep 151,468165651192
30 Jun 151,416140636191
31 Mar 151,374147606189
31 Dec 141,332154577187
30 Sep 141,310155557190
30 Jun 141,287156537193
31 Mar 141,284149543194
31 Dec 131,282142549196
30 Jun 131,28387571220
31 Mar 131,28092572234

Quality Earnings: IPN has high quality earnings.

Growing Profit Margin: IPN's current net profit margins (18.7%) are lower than last year (18.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IPN's earnings have grown significantly by 22% per year over the past 5 years.

Accelerating Growth: IPN's earnings growth over the past year (4%) is below its 5-year average (22% per year).

Earnings vs Industry: IPN earnings growth over the past year (4%) exceeded the Pharmaceuticals industry -0.5%.


Return on Equity

High ROE: IPN's Return on Equity (16.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.